Arrowhead Pharmaceuticals (ARWR) Cash & Equivalents (2016 - 2025)
Historic Cash & Equivalents for Arrowhead Pharmaceuticals (ARWR) over the last 16 years, with Q4 2025 value amounting to $201.6 million.
- Arrowhead Pharmaceuticals' Cash & Equivalents rose 27418.21% to $201.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $201.6 million, marking a year-over-year increase of 27418.21%. This contributed to the annual value of $226.5 million for FY2025, which is 12062.42% up from last year.
- Per Arrowhead Pharmaceuticals' latest filing, its Cash & Equivalents stood at $201.6 million for Q4 2025, which was up 27418.21% from $226.5 million recorded in Q3 2025.
- In the past 5 years, Arrowhead Pharmaceuticals' Cash & Equivalents registered a high of $372.4 million during Q1 2021, and its lowest value of $39.3 million during Q4 2021.
- Its 5-year average for Cash & Equivalents is $148.2 million, with a median of $128.8 million in 2024.
- Over the last 5 years, Arrowhead Pharmaceuticals' Cash & Equivalents had its largest YoY gain of 41512.66% in 2022, and its largest YoY loss of 7679.7% in 2022.
- Arrowhead Pharmaceuticals' Cash & Equivalents (Quarter) stood at $39.3 million in 2021, then surged by 415.13% to $202.2 million in 2022, then plummeted by 71.22% to $58.2 million in 2023, then fell by 7.43% to $53.9 million in 2024, then skyrocketed by 274.18% to $201.6 million in 2025.
- Its last three reported values are $201.6 million in Q4 2025, $226.5 million for Q3 2025, and $129.8 million during Q2 2025.